Works matching IS 02704137 AND DT 2025 AND VI 85 AND IP 1

Results: 14
    1
    2
    3
    4

    Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment.

    Published in:
    Prostate, 2025, v. 85, n. 1, p. 30, doi. 10.1002/pros.24797
    By:
    • Wong, Chris H.‐M.;
    • Ko, Ivan C.‐H.;
    • Leung, David K.‐W.;
    • Siu, Brian;
    • Cheng, Cheuk‐K. K.;
    • Lim, Yung‐Y. J.;
    • Mok, Hiu T.;
    • Kwok, Chun‐F. B.;
    • Tang, Cheuk Y.;
    • Leung, Steven C.‐H.;
    • Chiu, Peter K.‐F.;
    • Teoh, Jeremy Y.‐C.;
    • Ng, Chi F.
    Publication type:
    Article
    5

    Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts.

    Published in:
    Prostate, 2025, v. 85, n. 1, p. 82, doi. 10.1002/pros.24803
    By:
    • Finati, Marco;
    • Morrison, Chase;
    • Stephens, Alex;
    • Chiarelli, Giuseppe;
    • Cirulli, Giuseppe Ottone;
    • Tinsley, Shane;
    • Davis, Matthew;
    • Sood, Akshay;
    • Buffi, Nicolò;
    • Lughezzani, Giovanni;
    • Salonia, Andrea;
    • Briganti, Alberto;
    • Montorsi, Francesco;
    • Busetto, Gian Maria;
    • Bettocchi, Carlo;
    • Rogers, Craig;
    • Carrieri, Giuseppe;
    • Abdollah, Firas
    Publication type:
    Article
    6
    7

    Prostate cancer focal therapy: surgeon experience influences oncological results.

    Published in:
    Prostate, 2025, v. 85, n. 1, p. 58, doi. 10.1002/pros.24800
    By:
    • Murta, Claudio Bovolenta;
    • Júnior, José Pontes;
    • de Souza Filho, Pedro Humberto Felix;
    • de Godoy Júnior, Paulo Cezar;
    • Pugliesi, Felipe Guimarães;
    • El Hayek, Kayann Reda;
    • Gallucci, Fábio Pescarmona;
    • Guglielmetti, Giuliano Betoni;
    • de Almeida Claro, Joaquim Francisco
    Publication type:
    Article
    8
    9
    10

    Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.

    Published in:
    Prostate, 2025, v. 85, n. 1, p. 73, doi. 10.1002/pros.24802
    By:
    • Narita, Shintaro;
    • Yanagisawa, Takafumi;
    • Hatakeyama, Shingo;
    • Hata, Kenichi;
    • Fujita, Kazutoshi;
    • Ueda, Takashi;
    • Tanaka, Toshikazu;
    • Maita, Shinya;
    • Chiba, Shuji;
    • Sato, Hiromi;
    • Sekine, Yuya;
    • Kobayashi, Mizuki;
    • Kashima, Soki;
    • Yamamoto, Ryohei;
    • Numakura, Kazuyuki;
    • Saito, Mitsuru;
    • Takayama, Koichiro;
    • Okane, Katsumi;
    • Ishida, Toshiya;
    • Horikawa, Yohei
    Publication type:
    Article
    11

    Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa.

    Published in:
    Prostate, 2025, v. 85, n. 1, p. 21, doi. 10.1002/pros.24796
    By:
    • Tanaka, Nobumichi;
    • Izumi, Kouji;
    • Nakai, Yasushi;
    • Shima, Takashi;
    • Kato, Yuki;
    • Mita, Koji;
    • Kamiyama, Manabu;
    • Inoue, Shogo;
    • Hoshi, Seiji;
    • Okamura, Takehiko;
    • Yoshio, Yuko;
    • Enokida, Hideki;
    • Chikazawa, Ippei;
    • Kawai, Noriyasu;
    • Hashimoto, Kohei;
    • Fukagai, Takashi;
    • Shigehara, Kazuyoshi;
    • Takahara, Shizuko;
    • Mizokami, Atsushi
    Publication type:
    Article
    12
    13
    14

    Issue Information.

    Published in:
    Prostate, 2025, v. 85, n. 1, p. 1, doi. 10.1002/pros.24726
    Publication type:
    Article